

REMARKS

This application has been filed to pursue subject matter that was at issue in the parent application. The proposed claims are based on the claims originally filed and do not add new matter. Claim 21 is directed to novel compositions in which a single-chain glycoprotein hormone is non-covalently associated with an additional β subunit. This claim corresponds to claim 11 as originally filed. Claims 22-27 modify the composition of claim 21; these claims correspond to original claims 2-4, 6, 8 and 10. Although these claims were originally method claims, the restrictions on the composition correspond to those originally set forth in these claims.

New claim 28 is simply directed to a pharmaceutical formulation of claim 21 and claims 29-35 correspond to original claims 13-19 and are directed to recombinant methods for producing the novel compositions of claim 21. Since the patentability of the composition depends on its novelty and unobviousness, it is believed that the recombinant methods for its production are properly examined in the same application.

Claims 36-39 are methods to use the novel compositions and correspond to claims 1, 5, 7 and 9 as originally filed.


Entry of the amendment and examination on the merits are respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket No. 295002005901.

Respectfully submitted,

Dated: August 21, 2003

By:



Kate H. Murashige
Registration No. 29,959

Morrison & Foerster LLP
3811 Valley Centre Drive, Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125